SEGALA, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 4.257
EU - Europa 2.306
AS - Asia 656
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
SA - Sud America 5
AF - Africa 2
Totale 7.237
Nazione #
US - Stati Uniti d'America 4.249
IT - Italia 1.082
PL - Polonia 716
CN - Cina 422
DE - Germania 112
GB - Regno Unito 103
UA - Ucraina 95
SE - Svezia 87
VN - Vietnam 69
TR - Turchia 64
ID - Indonesia 53
FR - Francia 36
FI - Finlandia 29
BE - Belgio 13
IN - India 13
SG - Singapore 13
NL - Olanda 9
CA - Canada 7
HK - Hong Kong 7
IE - Irlanda 6
CH - Svizzera 5
EU - Europa 5
KR - Corea 5
AU - Australia 4
RU - Federazione Russa 4
CZ - Repubblica Ceca 3
IR - Iran 3
BR - Brasile 2
CL - Cile 2
ZA - Sudafrica 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BG - Bulgaria 1
CO - Colombia 1
DK - Danimarca 1
GE - Georgia 1
IL - Israele 1
IQ - Iraq 1
JP - Giappone 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SM - San Marino 1
TH - Thailandia 1
Totale 7.237
Città #
Warsaw 715
Fairfield 588
Ashburn 520
Chandler 356
Woodbridge 309
Beijing 246
Houston 237
Wilmington 236
Seattle 217
Cambridge 176
Princeton 155
Ferrara 125
Ann Arbor 111
Jacksonville 102
Milan 74
Dong Ket 69
San Diego 69
Bremen 60
Jakarta 53
Shanghai 53
Izmir 47
Washington 43
Boardman 39
Falls Church 37
Nanjing 37
Rome 36
Redwood City 31
Dearborn 27
Addison 26
London 25
Santa Maria Di Sala 22
New York 18
Bologna 17
Norwalk 16
Mountain View 15
San Mateo 15
Brussels 11
Shenyang 10
Verona 10
Nanchang 9
Tianjin 9
Los Angeles 8
Augusta 7
Ferrara di Monte Baldo 7
Helsinki 7
Jiaxing 7
Padova 7
Chicago 6
Hebei 6
Hong Kong 6
Jinan 6
Lappeenranta 6
Singapore 6
Andover 5
Auburn Hills 5
Castelnuovo Rangone 5
Chiswick 5
Cordenons 5
Feltre 5
Florence 5
Palermo 5
Taizhou 5
Arezzo 4
Hangzhou 4
Paris 4
Pisa 4
Torino 4
Turin 4
Zonguldak 4
Ancona 3
Brescia 3
Cagliari 3
Cascina 3
Catania 3
Chilly-mazarin 3
Des Moines 3
Dublin 3
Forlì 3
Guangzhou 3
Haikou 3
Hounslow 3
Kilburn 3
Kunming 3
Leawood 3
Modena 3
Mumbai 3
New Bedfont 3
North Wales 3
Parma 3
Trieste 3
Venezia 3
Verdellino 3
Villongo 3
Wuhan 3
Amsterdam 2
Ardabil 2
Camparada 2
Campobasso 2
Carate Brianza 2
Castellammare di Stabia 2
Totale 5.210
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 493
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 254
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 162
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 119
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 111
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 106
null 106
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 101
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 96
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 91
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 87
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 86
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 86
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 82
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 81
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 77
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 75
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 74
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 72
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 70
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 68
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 68
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 68
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 68
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 67
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 67
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 64
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 64
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 64
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 64
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 63
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 62
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 62
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 62
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 61
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 61
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 61
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 61
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 61
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 61
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 60
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 59
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 59
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 58
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 58
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 58
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 58
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 57
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 57
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 57
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 57
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 56
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 56
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 55
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 55
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 55
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 55
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 53
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 53
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 53
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 53
null 53
FOLLOW-UP SIEROLOGICO DI PAZIENTE AFFETTO DA RECIDIVA DI IDATIDOSI EPATICA ED INTOLLERANZA ALL’ALBENDAZOLO (ABZ). 52
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 52
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 52
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 51
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 49
null 48
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 48
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 47
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 46
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 46
null 46
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 46
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 46
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 46
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 45
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 44
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 44
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 42
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 41
RIACUTIZZAZIONE DI EPATITE CRONICA HBV-RELATA DOPO VACCINAZIONE ANTINFLUENZALE. DESCRIZIONE DI UN CASO CLINICO 40
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 40
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 39
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 39
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 39
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 39
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 39
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 38
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 38
Associations between immune depression and cardiovascular events in HIV infection 38
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 38
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 36
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 34
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 34
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 33
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 33
Impact of lamivudine monotherapy in failing patients with multidrug-resistant HIV: final 48 weeks results (MONO-AIFA FARM7PAZS3) 33
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 33
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 32
Totale 6.527
Categoria #
all - tutte 44.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 815
Totale 45.596


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201995 0 0 0 0 0 0 0 0 0 0 0 95
2019/20201.270 59 10 6 38 18 38 46 33 404 295 160 163
2020/20212.586 143 271 132 313 301 303 224 213 126 310 89 161
2021/20221.092 74 97 23 15 57 89 56 66 38 122 53 402
2022/20231.004 159 66 68 54 177 93 53 98 117 12 73 34
2023/2024934 55 100 83 42 116 225 27 74 34 29 37 112
Totale 7.592